← Cingulate Inc. (CING) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cingulate Inc. (CING)
Pharmaceutical Preparations · market cap $72M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Cingulate Inc. (CING) is a clinical-stage pharmaceutical company with a market cap of approximately $62M developing novel ADHD treatments built around dexmethylphenidate formulations. Its lead asset CTx-1301 (dexmethylphenidate 25mg) is in Phase 3, with earlier-stage pipeline variants at 12.5mg (titration) and 5mg (Phase 2). The company carries $25.9M in cash, representing roughly 11 months of runway at current burn, with no disclosed revenue.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dexmethylphenidate 5 Mg Oral Capsule, Extended Release | Phase 2 | ADHD |
| CTx-1301 - Dexmethylphenidate 25mg | Phase 3 | ADHD |
| CTx-1301-Dexmethylphenidate 12.5 mg (titration only) | Phase 3 | ADHD |
Price & technical context
3-month
+1.7%
6-month
-23.9%
12-month
+32.6%
52-wk range
$3.33–$11.66
vs 50-day MA
-4.4%
vs 200-day MA
-9.9%
Realized vol
88.7%
Max drawdown
-69.1%
Daily closes through 2026-09-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CING (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.